Skip to main content
Journal cover image

The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI.

Journal articles  - Journal Article, Multicenter Study
Januzzi, JL; Gibson, CM; Chi, G; Coller, BS; Granger, CB; Montalescot, G; Rikken, SAOF; Verburg, A; Berg, JMT; van 't Hof, AWJ ...
Published in: Am Heart J
November 2026

BACKGROUND: Among individuals with ST-segment elevation myocardial infarction (STEMI), a single subcutaneous injection of the short-acting glycoprotein IIb/IIIa receptor blocker antagonist zalunfiban at first medical contact significantly improved the primary outcome including clinical endpoints. The impact of zalunfiban on Myocardial Infarction (MI) size and association with downstream outcomes remains unclear. METHODS: In a prespecified analysis, we studied results among study participants treated with 2 doses of zalunfiban who had core laboratory measurements concentrations of hs-cTnT. RESULTS: More elevated hs-cTnT concentrations at presentation were associated with less resolution of ST deviation (P = .006) and more frequent Q wave development (P < .001). At coronary angiography more elevated hs-cTnT at presentation was associated with higher thrombus grade and worse epicardial and myocardial perfusion (all P < .05). In multivariable analyses, higher hs-cTnT concentrations at 24 hours were associated with greater adjusted risk for all-cause death (odds ratio [OR] 1.83 per log unit increase; P = .03), cardiovascular death (OR 1.83 per log unit increase; P = .03), heart failure (OR 2.74 per log unit increase; P < .001) or the composite of death and heart failure (P < .001) by 30 days. At 24 hours, those treated with zalunfiban had lower hs-cTnT compared to placebo (P = .04) and across multiples ≥ 10 to ≥ 1,000 times elevation, treatment with zalunfiban resulted in smaller hs-cTnT determined MI size. CONCLUSIONS: Among patients with STEMI, more elevated concentrations of hs-cTnT are associated with worse measures of reperfusion and higher-risk for short-term death or heart failure. A single dose of zalunfiban at first medical contact reduced MI size. TRIAL REGISTRATION: A phase 3 study of zalunfiban in subjects with ST-elevation MI (CELEBRATE); NCT04825743.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2026

Volume

301

Start / End Page

107513

Location

United States

Related Subject Headings

  • Treatment Outcome
  • ST Elevation Myocardial Infarction
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Humans
  • Female
  • Electrocardiography
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Januzzi, J. L., Gibson, C. M., Chi, G., Coller, B. S., Granger, C. B., Montalescot, G., … CELEBRATE Investigators. (2026). The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI. Am Heart J, 301, 107513. https://doi.org/10.1016/j.ahj.2026.107513
Januzzi, James L., C Michael Gibson, Gerald Chi, Barry S. Coller, Christopher B. Granger, Gilles Montalescot, Sem A. O. F. Rikken, et al. “The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI.” Am Heart J 301 (November 2026): 107513. https://doi.org/10.1016/j.ahj.2026.107513.
Januzzi JL, Gibson CM, Chi G, Coller BS, Granger CB, Montalescot G, et al. The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI. Am Heart J. 2026 Nov;301:107513.
Januzzi, James L., et al. “The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI.” Am Heart J, vol. 301, Nov. 2026, p. 107513. Pubmed, doi:10.1016/j.ahj.2026.107513.
Januzzi JL, Gibson CM, Chi G, Coller BS, Granger CB, Montalescot G, Rikken SAOF, Verburg A, Berg JMT, van ’t Hof AWJ, CELEBRATE Investigators. The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI. Am Heart J. 2026 Nov;301:107513.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2026

Volume

301

Start / End Page

107513

Location

United States

Related Subject Headings

  • Treatment Outcome
  • ST Elevation Myocardial Infarction
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
  • Injections, Subcutaneous
  • Humans
  • Female
  • Electrocardiography